Clinical development of cancer vaccines

2026/03/01 by John B. Haanen, Ton N. M. Schumacher, Jonathan C. Kagan +2 · 1 voice
Biochemistry, Genetics and Molecular Biology · Immunology and Microbiology · #Biological Research and Disease Studies #Immunotherapy and Immune Responses #vaccines and immunoinformatics approaches

paper · doi:10.1038/s41591-026-04241-9

crossref issued 2026/03/01 · crossref published 2026/03/01 · crossref published-print 2026/03/01 · openalex publication_date 2026/03/01 · crossref published-online 2026/03/11 · crossref created 2026/03/11 · openalex created_date 2026/03/12 · crossref deposited 2026/03/26 · crossref indexed 2026/07/30 · openalex updated_date 2026/07/31

Citations

• Toll-like Receptors and the Control of Immunity
• Structures and Mechanisms in the cGAS-STING Innate Immunity Pathway
• A Phase Ib Trial of Personalized Neoantigen Therapy Plus Anti-PD-1 in Patients with Advanced Melanoma, Non-small Cell Lung Cancer, or Bladder Cancer
• Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
• COVID-19 Vaccines: Adenoviral Vectors
• Therapeutic cancer vaccines
• Immunogenic cell stress and death
• Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer
• RNA neoantigen vaccines prime long-lived CD8+ T cells in pancreatic cancer

Discussions

• 🙌 Self-promotion: Ok, one of us is an author on this excellent review on cancer vaccines doi.org/10.1038/s415... [bsky, 2 points, 0 comments]